Free tool
FAERS Monitor: Azor
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022100 or its brand name (Azor, Amlodipine Besylate, Olmesartan Medoxomil). Reports on generic versions are filed under their own applications.
Reports
2,511
Serious
1,462
58% of reports
Hospitalization
880
Death reported
91
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- sprue-like enteropathy327
- gastrooesophageal reflux disease210
- diarrhoea183
- dizziness180
- acute kidney injury170
- weight decreased166
- drug ineffective147
- nausea138
- haemorrhoids133
- chronic kidney disease126
- constipation116
- fatigue111
- headache98
- asthenia95
- flushing93
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 2 |
| 2008 | 36 |
| 2009 | 101 |
| 2010 | 164 |
| 2011 | 176 |
| 2012 | 205 |
| 2013 | 117 |
| 2014 | 113 |
| 2015 | 379 |
| 2016 | 333 |
| 2017 | 239 |
| 2018 | 287 |
| 2019 | 134 |
| 2020 | 72 |
| 2021 | 42 |
| 2022 | 21 |
| 2023 | 22 |
| 2024 | 22 |
| 2025 | 27 |
| 2026 | 19 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,648 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sprue-like enteropathySignal | 327 | 595.1 | 535.7 | 180,570 |
| haemorrhoidsSignal | 133 | 57.5 | 48.7 | 7,283 |
| gastrooesophageal reflux diseaseSignal | 210 | 21.9 | 19.2 | 4,174 |
| chronic kidney diseaseSignal | 126 | 13.9 | 11.7 | 1,500 |
| acute kidney injurySignal | 170 | 9.3 | 8.1 | 1,261 |
| flushingSignal | 93 | 7.7 | 6.3 | 535 |
| weight decreasedSignal | 166 | 5.0 | 4.3 | 531 |
| constipationSignal | 116 | 4.5 | 3.7 | 311 |
| dizzinessSignal | 180 | 3.0 | 2.6 | 248 |
| diarrhoeaSignal | 183 | 2.4 | 2.1 | 149 |
| astheniaSignal | 95 | 2.1 | 1.7 | 56 |
| nausea | 138 | 1.5 | 1.2 | 20 |
| headache | 98 | 1.3 | 1.1 | 7 |
| fatigue | 111 | 1.2 | 1.0 | 3 |
| drug ineffective | 147 | 0.9 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.